Tuberculosis preventive treatment among individuals with inactive tuberculosis suggested by untreated radiographic abnormalities: a community-based randomized controlled trial

References

• Hartman-Adams H, Clark K, Juckett G. Update on latent tuberculosis infection. Am Fam Physician. 2014;89(11):889–896.
   PubMed Web of Science ®Google Scholar
• Leung CC, Rieder HL, Lange C, et al. Treatment of latent infection with Mycobacterium tuberculosis: update 2010. Eur Respir J. 2011;37(3):690–711.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO consolidated guidelines on tuberculosis. Geneva: World Health Organization; 2020.
   Google Scholar
• American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep. 2000;49(Rr-6):1–51.
   Google Scholar
• Public Health Agency of Canada. Canadian tuberculosis standards. 7th ed. Ottawa (ON): Public Health Agency of Canada; 2014.
   Google Scholar
• Xin H, Zhang H, Yang S, et al. 5-Year follow-up of active tuberculosis development from latent infection in rural China. Clin Infect Dis. 2020;70(5):947–950.
   PubMed Web of Science ®Google Scholar
• Gao L, Li X, Liu J, et al. Incidence of active tuberculosis in individuals with latent tuberculosis infection in rural China: follow-up results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis. 2017;17(10):1053–1061.
   PubMed Web of Science ®Google Scholar
• Gao L, Zhang H, Xin H, et al. Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study. Eur Respir J. 2018;52(6):1801470.
   PubMed Web of Science ®Google Scholar
• Xin H, Cao X, Zhang H, et al. Protective efficacy of 6-week regimen for latent tuberculosis infection treatment in rural China: 5-year follow-up of a randomised controlled trial. Eur Respir J. 2022;60(1):210235.
   Web of Science ®Google Scholar
• National Health Commission of the People’s Republic of China. Technical specification for tuberculosis prevention and control in China (2020 edition). [cited 2022 Oct 16]. Available from: https://tb.chinacdc.cn/ggl/202004/P020200414515703939844.pdf.
   Google Scholar
• Technical Guidance Group of the Fifth National TB Epidemiological Survey. The office of the fifth National TB epidemiological survey. The fifth national tuberculosis epidemiological survey in 2010. Chin J Antitubercul. 2012;34(8):485–508.
   Google Scholar
• National Health and Family Planning Commission of the People’s Republic of China. Diagnostic criteria for tuberculosis (WS288-2017). Elec J Emerg Infect Dis. 2018;3(1):65–67.
   Google Scholar
• National Health Commission of the People’s Republic of China. Classification of tuberculosis (WS196-2017); 2017.
   Google Scholar
• Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–2166.
   PubMed Web of Science ®Google Scholar
• Gao L, Lu W, Bai L, et al. Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis. 2015;15(3):310–319.
   PubMed Web of Science ®Google Scholar
• Comstock GW. Isoniazid prophylaxis in an undeveloped area. Am Rev Respir Dis. 1962;86:810–822.
   PubMed Web of Science ®Google Scholar
• Mount FW, Ferebee SH. The effect of isoniazid prophylaxis on tuberculosis morbidity among household contacts of previously known cases of tuberculosis. Am Rev Respir Dis. 1962;85:821–827.
   PubMed Web of Science ®Google Scholar
• Swindells S, Ramchandani R, Gupta A, et al. One month of Rifapentine plus Isoniazid to prevent HIV-related tuberculosis. N Engl J Med. 2019;380(11):1001–1011.
   PubMed Web of Science ®Google Scholar
• Villarino ME, Scott NA, Weis SE, et al. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr. 2015;169(3):247–255.
   PubMed Web of Science ®Google Scholar
• Menzies D, Adjobimey M, Ruslami R, et al. Four months of Rifampin or nine months of Isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379(5):440–453.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines on the management of latent tuberculosis infection. Geneva: World Health Organization; 2015.
   Google Scholar
• World Health Organization. Latent tuberculosis infection-updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018.
   Google Scholar
• Snider DE Jr, Farer LS. Preventive therapy with isoniazid for “inactive” tuberculosis. Chest. 1978;73(1):4–6.
   PubMed Web of Science ®Google Scholar
• Katz J, Kunofsky S, Damijonaitis V, et al. Effect of isoniazid upon the reactivation of inactive tuberculosis; final report. Am Rev Respir Dis. 1965;91:345–350.
   PubMedGoogle Scholar
• Grzybowski S, Ashley MJ, Pinkus G. Chemoprophylaxis in inactive tuberculosis: long-term evaluation of a Canadian trial. Can Med Assoc J. 1976;114(7):607–611.
   PubMed Web of Science ®Google Scholar
• Cheng J, Sun YN, Zhang CY, et al. Incidence and risk factors of tuberculosis among the elderly population in China: a prospective cohort study. Infect Dis Poverty. 2020;9(1):13.
   PubMed Web of Science ®Google Scholar
• Liu J, Liang W, Jing W, et al. Countdown to 2030: eliminating hepatitis B disease, China. Bull World Health Organ. 2019;97(3):230–238.
   PubMed Web of Science ®Google Scholar
• Yue T, Zhang Q, Cai T, et al. Trends in the disease burden of HBV and HCV infection in China from 1990–2019. Int J Infect Dis. 2022;122:476–485.
   PubMed Web of Science ®Google Scholar
• Kim WS, Lee SS, Lee CM, et al. Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury. BMC Infect Dis. 2016;16:50.
   PubMed Web of Science ®Google Scholar
• Lomtadze N, Kupreishvili L, Salakaia A, et al. Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis. PLoS One. 2013;8(12):e83892.
   PubMed Web of Science ®Google Scholar
• Agha MA, El-Mahalawy II, Seleem HE-DM, et al. Prevalence of hepatitis C virus in patients with tuberculosis and its impact in the incidence of anti-tuberculosis drugs induced hepatotoxicity. Eur Respir J. 2015;64:91–96.
   Google Scholar
• National Center for AIDS & STD Control and Prevention. The Chinese Center for Disease Control and Prevention (CDC). Annals of information on comprehensive prevention and treatment for AIDS, STD and Hepatitis C. Beijing, China; 2020.
   Google Scholar